ArticleHypertension (Dallas, Tex. : 1979)2021
Adverse Health Outcomes Associated With Refractory and Treatment-Resistant Hypertension in the Chronic Renal Insufficiency Cohort.
Article in Hypertension (Dallas, Tex. : 1979), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Impact of patient care teams on blood pressure control in patients with hypertension: a systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Pooled it
- Refractory Hypertension: a Narrative Systematic Review with Emphasis on Prognosis.Current hypertension reports · 2022Pooled it
- Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension.Hypertension (Dallas, Tex. : 1979) · 2026Trial
- Patients' Experiences of Outcome Expectations in Renal Denervation: A Qualitative Study.Healthcare (Basel, Switzerland) · 2026Article
- Associations of insulin resistance surrogate with resistant hypertension and the severity of hypertension in the chronic kidney disease population.Journal of hypertension · 2025Article
- Keratinocyte-specific angiotensin II receptor-associated protein deficiency exacerbates angiotensin II-dependent hypertension via activation of the skin renin-angiotensin system.Nature communications · 2025Article
- Resistant Hypertension: Disease Burden and Emerging Treatment Options.Current hypertension reports · 2024Review
- The Global Burden of Resistant Hypertension and Potential Treatment Options.European cardiology · 2024Review
- The renal artery-aorta angle associated with renal artery plaque: a retrospective analysis based on CT.BMC medical imaging · 2023Article
- A systems biology approach identifies the role of dysregulated PRDM6 in the development of hypertension.The Journal of clinical investigation · 2023Article
- Prevalence, Predictors, and Outcomes of Resistant Hypertension in Egyptian Population.Global heart · 2023Article
- Resistant Hypertension in Chronic Kidney Disease: A Burden unto Itself.Clinical journal of the American Society of Nephrology : CJASN · 2022Article
- An Update on Refractory Hypertension.Current hypertension reports · 2022Review
- Clinical Effect of Mudan Granule on Peripheral Neuritis Caused by Chronic Renal Insufficiency.Computational and mathematical methods in medicine · 2022Article
- Pathophysiologically based antihypertensive pharmacotherapeutics rationality, efficacy and safety in Sub Saharan African Nations - A review.International journal of cardiology. Cardiovascular risk and prevention · 2021Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
Refractory hypertension (RfH) is a severe phenotype of antihypertension treatment failure. Treatment-resistant hypertension (TRH), a less severe form of difficult-to-treat hypertension, has been associated with significantly worse health outcomes. However, no studies currently show how health outcomes may worsen upon progression to RfH. RfH and TRH were studied in 3147 hypertensive participants in the CRIC (Chronic Renal Insufficiency Cohort study). The hypertensive phenotype (ie, no TRH or RfH, TRH, or RfH) was identified at the baseline visit, and health outcomes were monitored at subsequent visits. Outcome risk was compared using Cox proportional hazards models with time-varying covariates. A total of 136 (4.3%) individuals were identified with RfH at baseline. After adjusting for participant characteristics, individuals with RfH had increased risk for the composite renal outcome across all study years (50% decline in estimated glomerular filtration rate or end-stage renal disease; hazard ratio for study years 0-10=1.73 [95% CI, 1.42-2.11]) and the composite cardiovascular disease outcome during later study years (stroke, myocardial infarction, or congestive heart failure; hazard ratio for study years 0-3=1.25 [0.91-1.73], for study years 3-6=1.50 [0.97-2.32]), and for study years 6-10=2.72 [1.47-5.01]) when compared with individuals with TRH. There was no significant difference in all-cause mortality between those with refractory versus TRH. We provide the first evidence that RfH is associated with worse long-term health outcomes compared with TRH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.